[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:constipation":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,58,89,126,151,175,192,220,243,268,294,322,344,366,389,412,433,456,495,518,543,565,586,608,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100643888","glp-1-receptor-agonists-and-early-proctologic-effects-in-morbid-obesity-100643888",false,"NCT07668765","GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity","Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment","GLP-PROCT","Inclusion Criteria:\n\n* Age ≥18 years\n* Morbid obesity (BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities)\n* Newly prescribed GLP-1 receptor agonist therapy\n* Ability and willingness to provide written informed consent\n* Ability to attend 3-month follow-up visit\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Perianal Crohn's disease\n* History of anorectal malignancy\n* Previous pelvic radiotherapy\n* Anorectal surgery within the previous 3 months\n* Pregnancy\n* Neurogenic bowel dysfunction\n* Inability to comply with follow-up visits\n* Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment\n* Active anorectal infection or abscess","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","3 Months","OBSERVATIONAL","Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.",[27,28,29,30,31],"Morbid Obesity","Anorectal Diseases","Drug-Related Side Effects and Adverse Reactions","Constipation","Diarrhea",[33,34,35,36,37,38,39,40,41,42,43,44],"GLP-1 receptor agonist","obesity","anorectal symptoms","hemorrhoids","anal fissure","constipation","semaglutide","tirzepatide","proctologic examination","bowel habits","anorectal disease","proctology","NOT_YET_RECRUITING","2026-06-23",{"date":48,"type":49},"2026-06-25","ACTUAL",{"date":51,"type":22},"2026-08",{"date":53,"type":22},"2027-05",{"name":55,"class":56},"Gazi University","OTHER",1,{"id":59,"slug":60,"hasResults":12,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":57},"100641433","test-anxiety-on-bowel-health-and-constipation-in-students-100641433","NCT07654959","Test Anxiety on Bowel Health and Constipation in Students","The Effect of Test Anxiety on Bowel Health and Constipation in University Students","Inclusion Criteria:\n\n* Being an undergraduate student in the Department of Physiotherapy and Rehabilitation at Lokman Hekim University\n* Being in the final examination period during the data collection process\n* Having sufficient reading and comprehension skills to complete the questionnaires independently\n* Voluntarily agreeing to participate in the study after reading and signing the informed consent form\n\nExclusion Criteria:\n\n* Having inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, celiac disease, colorectal cancer, or a history of major gastrointestinal surgery\n* Having diagnosed irritable bowel syndrome or another organic gastrointestinal disease\n* Regular use of laxatives or medications that directly affect bowel movements, such as opioids\n* Having neurological diseases that may affect bowel function, such as multiple sclerosis, Parkinson's disease, or spinal cord injury\n* Having had an acute gastrointestinal infection within the last month",true,{"count":67,"type":22},200,"This observational cross-sectional study aims to examine the relationship between test anxiety, bowel health, and constipation in university students. The study will include undergraduate students aged 18 years and older who are studying in the Physiotherapy and Rehabilitation Department at Lokman Hekim University and who are in their final examination period.\n\nParticipants will complete self-report questionnaires during a single face-to-face assessment session. Constipation status will be evaluated using the Rome IV criteria, stool form will be assessed using the Bristol Stool Scale, constipation severity will be assessed using the Constipation Severity Instrument, and test anxiety level will be assessed using the Test Anxiety Inventory. Sociodemographic characteristics and bowel-related symptoms will also be recorded.\n\nThe study does not include any intervention or treatment. The findings are expected to help better understand whether test anxiety during examination periods is associated with bowel health problems and constipation in university students.",[70,71,30],"Anxiety","Bowel Habits",[73,74,75,76,77],"Test anxiety","Examination stress","Bowel health","Rome IV criteria","University students","RECRUITING","2026-06-17",{"date":81,"type":49},"2026-06-22",{"date":83,"type":49},"2026-02-25",{"date":85,"type":22},"2027-02-25",{"name":87,"class":88},"Lokman Hekim University","OTHER_GOV",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":24,"phases":4,"briefSummary":99,"conditions":100,"keywords":109,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":57},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388","NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial",{"count":97,"type":22},5000,"10 Years","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[101,102,103,104,105,30,106,107,108],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[110,111,112,113,114,115,116,103],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","2026-06-15",{"date":119,"type":49},"2026-06-16",{"date":121,"type":49},"2014-11-01",{"date":123,"type":22},"2026-11",{"name":125,"class":56},"Indiana University",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":136,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":57},"100642940","phase-1-research-on-the-efficacy-and-mechanism-of-shouhui-tongbian-capsules-in-treating-postoperative-constipation-of-benign-anal-and-rectal-diseases-based-on-gut-microbiota-analysis-100642940","NCT07648394","Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis","Inclusion Criteria: Age between 18 and 75 years old, male or female. Undergoing surgery for benign anorectal diseases (e.g., mixed hemorrhoids, anal fistula, anal fissure).\n\nMeeting the diagnostic criteria for postoperative constipation (e.g., fewer than 3 spontaneous bowel movements per week, or difficulty in defecation).\n\nAble to understand the study procedures and voluntarily sign the informed consent form.\n\nAble to cooperate with medication administration, follow-up visits, and data collection.\n\nExclusion Criteria:Severe organic diseases of the heart, liver, kidney, or other vital organs.\n\nHistory of inflammatory bowel disease, irritable bowel syndrome, or severe chronic constipation unrelated to surgery.\n\nHistory of gastrointestinal surgery (other than the planned anorectal surgery) within the past 3 months.\n\nPregnancy, breastfeeding, or planned pregnancy during the study period (for female participants).\n\nKnown allergy or contraindication to the study drugs (Shouhui Tongbian Capsules or lactulose).\n\nCurrent use of other laxatives, prokinetic drugs, or traditional Chinese medicine for constipation within 1 month before enrollment.\n\nSevere mental disorders, cognitive impairment, or inability to communicate effectively.\n\nParticipation in other clinical trials within the past 3 months. Any other condition judged by the investigator to make the participant unsuitable for this study.","75 Years",{"count":134,"type":22},120,"INTERVENTIONAL",[137,138],"PHASE1","PHASE2","Study Title A study to learn how Shouhui Tongbian Capsules works to relieve constipation after anorectal surgery, and explore its effects linked to gut bacteria.\n\nWhy we do this study Constipation is a common problem after surgery for hemorrhoids, anal fistula and other benign anorectal diseases. It causes pain, slows wound healing and lowers quality of life. Traditional laxatives may lead to stomach pain, electrolyte problems and drug dependence.\n\nShouhui Tongbian Capsules is a traditional Chinese herbal medicine. It can ease constipation and protect the intestinal tract at the same time. This research aims to check how well this medicine works for post-surgery constipation, whether it reduces pain, and find out its working mechanism related to gut microbiota. We also want to collect evidence for better combined traditional Chinese and Western medicine treatment in clinic.\n\nWho can take part Adults aged 18 to 75 who receive surgery for benign anorectal diseases and have constipation Fully aware of the study and willing to sign an informed consent form People with severe organ diseases, mental illness, cancer, bleeding disorders, pregnancy or other conditions will not be included.\n\nHow the study works\n\nThis is a prospective, randomized, controlled clinical trial. A total of 120 patients will be randomly divided into two groups (60 people each):\n\nTest group: Take Shouhui Tongbian Capsules, 2 pills three times a day for 8 weeks.\n\nControl group: Take lactulose oral solution, the common medicine for constipation.\n\nWe will assess symptoms regularly before, during and after treatment. We will record constipation severity, traditional Chinese medicine symptom scores, pain scores (VAS), quality of life (SF-36), physical signs and blood test results. We will also test gut bacteria and inflammation levels to analyze the medicine's mechanism.\n\nSafety All participants will be closely monitored throughout the study. We will record any discomfort or side effects in a timely manner to ensure safety.\n\nExpected benefits This study will confirm the effectiveness and safety of Shouhui Tongbian Capsules for post-anorectal surgery constipation. It may help relieve your constipation and post-operative pain, speed up recovery and improve daily life. The results will also help doctors choose better treatments for similar patients in the future.\n\nStudy timeline May - June 2026: Complete ethical review and study preparation July - September 2026: Recruit participants and start treatment Late 2026 - Early 2027: Finish data collection, analysis and paper writing",[141,28,142,30],"Intestinal Flora","Surgery","2026-06-10",{"date":117,"type":49},{"date":146,"type":22},"2026-08-01",{"date":148,"type":22},"2027-06-30",{"name":150,"class":56},"China-Japan Friendship Hospital",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":135,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":57},"100633651","adults-with-constipation-100633651","NCT07529457","Adults With Constipation","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Men and women aged between 18 and 65 years;\n2. Participants presenting with constipation, characterized by \\\u003C3 spontaneous bowel movements per week or BSFS stool types 1-2;\n3. Capable of following the study protocol and completing all required assessments; Individuals who have voluntarily signed the informed consent form;\n4. No plans for pregnancy from at least 14 days prior to screening through 6 months after the study, with agreement to use reliable contraception methods.\n\nExclusion Criteria:\n\n1. Intake of similar functional products within a short period prior to enrollment that could influence study results;\n2. Participants who significantly alter their habitual diet during the trial;\n3. Individuals with severe allergic conditions or impaired immune function;\n4. Women who are pregnant, lactating, or intending to conceive;\n5. Patients with serious underlying diseases affecting major organs or metabolic systems;\n6. Antibiotic treatment within 2 weeks before enrollment;\n7. Individuals with severe mental or psychological disorders;\n8. Non-compliance with study requirements, including improper intake or missed follow-ups;\n9. Other subjects considered inappropriate for participation by the investigator.","65 Years",{"count":160,"type":22},70,[162],"NA","This randomized, double-blind, placebo-controlled trial will assess the clinical effects of Akk09 in adults with functional constipation. Participants will receive Akk09 or placebo for 4 weeks. The study will evaluate changes in bowel habits and symptom burden, as well as alterations in host inflammatory status, immune modulation, microbial ecosystem dynamics, neuroendocrine signaling related to the gut-brain axis, and systemic metabolic responses, to characterize the overall physiological impact of BC09 supplementation.",[30],"2026-06-05",{"date":167,"type":49},"2026-06-09",{"date":169,"type":22},"2026-05-10",{"date":171,"type":22},"2027-05-20",{"name":173,"class":174},"Wecare Probiotics Co., Ltd.","INDUSTRY",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":158,"enrollmentInfo":182,"targetDuration":4,"studyType":135,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":57},"100628503","probiotic-improve-constipation-100628503","NCT07462481","Probiotic Improve Constipation","A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Probiotics in Relieving Constipation in Adults","Inclusion Criteria:\n\n(1) Age 18-65 years; (2) Constipated patients (less than 3 bowel movements per week and\u002For Bristol Scale type 1 and 2); (3) Able to complete the study according to the trial protocol; (4) Patients who have signed the informed consent form; (5) Study participants (including male study participants) have no plans to have children within 14 days prior to screening and within 6 months after the end of the trial and voluntarily use effective contraception.\n\n\\-\n\nExclusion Criteria:\n\n1. Those who have taken a substance with a similar function to the test subject in a short period of time, affecting their judgment of the results;\n2. Patients who changed their diet during the study;\n3. Patients with severe allergies and immunodeficiency;\n4. Pregnant, breastfeeding, or women planning to become pregnant;\n5. Those with severe diseases of vital organs such as the cardiovascular system, lungs, liver, and kidneys, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, or severe immune system diseases;\n6. Those who have used antibiotics in the past two weeks;\n7. Those with severe psychological or mental illnesses;\n8. Those who did not consume the test sample as required or did not follow up on time, resulting in the inability to determine the efficacy;\n9. Other study participants deemed unsuitable by the researchers. -",{"count":183,"type":22},105,[162],"To evaluate the efficacy and safety of probiotic as a food supplement in regulating bowel habits in patients with chronic constipation, and to compare it with placebo.",[30],{"date":167,"type":49},{"date":143,"type":22},{"date":190,"type":22},"2027-08-01",{"name":173,"class":174},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":135,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100599945","a-study-of-herbal-supplements-in-cancer-survivors-with-constipation-100599945","NCT07091084","A Study of Herbal Supplements in Cancer Survivors With Constipation","Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)","Inclusion Criteria:\n\n* Age 18 years or greater;\n* A diagnosis of cancer with no restrictions placed on type of cancer or stage;\n* Completed surgery, chemotherapy, immunotherapy, and\u002For radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;\n* Karnofsky functional score of ≥ 60;\n* Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:\n\n  * Straining more than 25% of defecations.\n  * Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.\n  * Sensation of incomplete evacuation more than one-fourth (25%) of defecations.\n  * Sensation of anorectal obstruction\u002Fblockage more than one-fourth (25%) of defecations.\n  * Manual maneuvers to facilitate more than one-fourth (25%) of defecations.\n  * Fewer than three spontaneous bowel movements per week.\n  * Loose stools are rarely present without the use of laxatives.\n  * Insufficient criteria for irritable bowel syndrome.\n* Patient should be able to understand and complete all study assessments on their own\n* Patient should be able to understand and provide signed informed consent in English.\n\nTable 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\\*\n\n1. Must include two or more of the following:\\*\\*\n2. Straining during more than ¼ (25%) of defecations\n3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations\n4. Sensation of incomplete evacuation more than ¼ (25%) of defecations\n5. Sensation of anorectal obstruction\u002Fblockage more than ¼ (25%) of defecations\n6. Fewer than three SBM per week\n7. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)\n\n9\\. Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note \\*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis\n\nExclusion Criteria:\n\n* Patients who have allergic history to herbs or Chinese medicine;\n* Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL\u002Fmin\u002F1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);\n* Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;\n* Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;\n* Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.",{"count":160,"type":22},[162],"The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.",[30,203,204],"Cancer","Functional Constipation",[38,206,207,208,209,210],"functional constipation","Ma-Zi-Ren-Wan","MZRW","25-076","Memorial Sloan Kettering Cancer Center","2026-05-20",{"date":213,"type":49},"2026-05-22",{"date":215,"type":49},"2025-07-15",{"date":217,"type":22},"2028-07-15",{"name":210,"class":56},7,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":228,"targetDuration":4,"studyType":135,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":57},"100634906","phase-2-a-study-of-brenipatide-ly3537031-in-participants-with-irritable-bowel-syndrome-constipation-ibs-c-100634906","NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C","RENEW-IBS-C","Inclusion Criteria:\n\n* Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n\nExclusion Criteria:\n\n* Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality",{"count":229,"type":22},342,[138],"The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[233,30],"Irritable Bowel Syndrome","2026-05-11",{"date":236,"type":49},"2026-05-13",{"date":238,"type":49},"2026-04-29",{"date":240,"type":22},"2027-09",{"name":242,"class":174},"Eli Lilly and Company",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":250,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":135,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":57},"100627082","randomized-blinded-placebo-controlled-evaluation-of-bioamicus-complete-100627082","NCT07444008","Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete","A Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Dietary Supplement BioAmicus Complete (Oral Drops; a Mixture of 10 Strains of Lacto- and Bifidobacteria) in Managing Functional Gastrointestinal Disorders and Cutaneous Symptoms of Food Allergy in Infants During the First Months of Life","Inclusion Criteria:\n\n* The child's parents\u002Fguardians speak Russian, have been informed about the study's purpose, understand its essence, are aware of their rights, and have signed the informed consent form.\n* Diarrhea or constipation accompanied by colic and\u002For regurgitation (gastroesophageal reflux, GER).\n* Cutaneous manifestations of food allergy.\n* The child was born at term or preterm, but not before the 7th month of gestation.\n* Age at the time of parental informed consent: from 1 month to 4 months and 28 days.\n* The child is on breastfeeding, formula feeding, or mixed feeding.\n* The child has no other health conditions that would require a specialized diet.\n* The parents\u002Fguardians are able and willing to regularly complete the proposed observation diary form.\n\nExclusion Criteria:\n\n* The child has a congenital pathology or any other conditions\u002Fdiseases\u002Fclinical manifestations that may interfere with participation in the study.\n* Use of lactase supplements.\n* Use of other probiotic products, antibiotics, enteral antiseptics, antifungal, or antiprotozoal medications.\n* The child was born preterm (before the 7th month of gestation).","1 Month","5 Months",{"count":253,"type":22},140,[162],"This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional gastrointestinal disorders and cutaneous symptoms of food allergy in infants during the first months of life.\n\nThe aim of the study is to assess clinical effects of BioAmicus Complete drops on the symptoms of infantile colic, constipation, diarrhea, gastroesophageal reflux, atopic dermatitis\u002Feczema in full-term newborns during the first months of life.\n\nA prospective study comparing two treatment groups:\n\nGroup 1 (treatment group) - 70 infants. Group 2 (control group) - 70 infants, placebo. The study drug will be taken in 1 time per day within 25 days. Allowed symptomatic therapy includes defoamers (simethicone-based preparations), carminative preparations (dill water (fenhel)), etc.",[257,30,258,259],"Infantile Colics","Infantile Diarrhea","Atopic Dermatitis","2026-05-06",{"date":234,"type":49},{"date":263,"type":49},"2026-03-16",{"date":265,"type":22},"2026-07-30",{"name":267,"class":174},"NovoNatum Ltd",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":135,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":57},"100599369","efficacy-of-lcs-fermented-milk-on-constipation-related-symptoms-in-filipino-adults-100599369","NCT07083596","Efficacy of LcS-Fermented Milk on Constipation-Related Symptoms in Filipino Adults","The Efficacy of Fermented Milk Drink With Lacticaseibacillus Paracasei Strain Shirota (LcS) on Relieving Constipation-Related Symptoms of Filipino Adults","Inclusion Criteria:\n\n* Filipino adult male or female aged 18 to 59 years old\n* Apparently healthy adults with constipation-related symptoms of hard to lumpy stools (Bristol Stool Form Scale 1-2) in 25% or more of defecations in a week\n* With cold storage at home\n\nExclusion Criteria:\n\n1. Habitual intake of food items containing probiotics and prebiotics as food supplements (previous 3 months, at least three times per week)\n2. Constipation due to organic or neurologic origin\n3. High fiber intake (\\>30 g\u002Fday)\n4. Pregnant or lactating\n5. Allergy to dairy products and\u002For lactose intolerance\n6. Use of laxatives, anticholinergics and medications for constipation or diarrhea within the past three months\n7. Use of antibiotics within the past two weeks\n8. Presence of chronic diseases such as diabetes mellitus and its complications, cardiovascular diseases, kidney problems\n9. GI condition that may interfere with the evaluation of the outcome such as hemorrhoids, intestinal obstruction and inflammatory bowel diseases\n10. Recent history of any gastrointestinal surgery\n11. Have pre-existing medical conditions like hypo- or hyperthyroidism and congenital abnormalities\n12. Participation in another study with test product two months prior the study","59 Years",{"count":277,"type":22},60,[162],"The primary purpose of this study is to investigate whether the consumption of a probiotic drink (with Lacticaseibacillus paracasei strain Shirota (LcS)) relieves constipation-related symptoms of Filipino adults, specifically its effect on stool consistency, frequency, and duration, and on gastrointestinal discomfort.",[30,281],"Gastrointestinal Discomfort",[283,284,38],"probiotic","Lacticaseibacillus paracasei strain Shirota","2026-04-27",{"date":287,"type":49},"2026-05-04",{"date":289,"type":22},"2026-04-22",{"date":291,"type":22},"2026-10",{"name":293,"class":56},"University of Santo Tomas",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":135,"phases":304,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":57},"100633097","phase-3-rifaximin-treatment-in-bloating-predominant-functional-bowel-disorders-100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.","80 Years",{"count":303,"type":22},78,[305],"PHASE3","This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[308,309,310,233,30],"Bloating","Rifaximin","Functional Bowel Disorder",[309,308,312],"Functional bowel disorder","2026-04-03",{"date":315,"type":49},"2026-04-13",{"date":317,"type":22},"2026-04",{"date":319,"type":22},"2027-12",{"name":321,"class":56},"Mahidol University",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":135,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":57},"100609497","impact-of-the-inno-cleanse-dietary-supplement-on-gut-health-and-associated-variables-in-healthy-men-and-women-100609497","NCT07215351","Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women","Inclusion Criteria:\n\n* experience regular (2 or more days per week) bloating or constipation\n* able to fast a minimum of 12 hours prior to testing visit\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant, or breastfeeding\n* sensitivity or allergic to any components of the study product (cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, cellulose, and silicon dioxide).\n* experienced a severe allergic reaction that resulted in emergency care\n* diagnosed with medical disorders linked to digestive\u002Fgut health such as celiac disease, crohn's disease, gastroesophageal reflux disease, heartburn, irritable bowel syndrome, ulcerative colitis, ulcers, etcetera.\n* experiencing regular diarrhea\n* active infection or illness\n* diabetic\n* hypertensive\n* cardiovascular disease\n* breast, uterine, or ovarian cancer\n* uterine fibroids or endometriosis\n* taking medications or supplements that may alter gut health including but not limited to diuretics, laxatives, anti-diarrheal, anticholinergic agents, or antispasmodic agents.\n* previous adverse experience with laxatives\n* taking medications known to interact with the dietary supplement's ingredients including blood pressure medications, anticoagulants, antiplatelets, blood thinners, cholesterol-lowering medications, diuretics, water pills, estrogen based contraceptives, non-steroidal anti-inflammatory drugs, digoxin, corticosteroids, Monoamine oxidase inhibitors, insulin, medications processed in the liver, diclofenac, fluvastatin, glipizide, ibuprofen, piroxicam, phenytoin, phenobarbital, or secobarbital.\n* tobacco user\n* strenuous activity within 24 hours of testing visits\n* caffeine within 24 hours of testing visit\n* alcohol within 24 hours of testing visit",{"count":329,"type":22},30,[162],"The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months.\n\nDespite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness.\n\nTherefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.",[30,308],[334],"Inno Cleanse","2026-04-01",{"date":337,"type":49},"2026-04-02",{"date":339,"type":49},"2025-10-07",{"date":341,"type":22},"2026-05-01",{"name":343,"class":56},"University of Memphis",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":351,"targetDuration":4,"studyType":135,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":57},"100578351","phase-3-assessing-tenapanor-as-a-treatment-of-cf-related-constipation-100578351","NCT06810167","Assessing Tenapanor as a Treatment of CF-related Constipation.","An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.","Inclusion Criteria:\n\n1. Having confirmed cystic fibrosis (either by sweat chloride or genetic testing)\n2. Meeting criteria for CFrC\n\n   Must include 2 of the following, with or without abdominal pain for at least 3 months, with symptom onset at least 6-months prior:\n   * Straining in at least 25% of defecations\n   * Bristol Stool Scale 1-2 more than 25% of defecations (change in stool form)\n   * Sensation of incomplete evacuation more than 25% of defecations\n   * Sensation of anorectal obstruction\u002Fblockage more than 25% of defecations\n   * Manual disimpaction\u002Fmanipulation of pelvic floor to facilitate more than 25% of defecations\n   * Fewer than 3 spontaneous bowel movements weekly (change in stool frequency)\n   * Loose stools rarely present without the use of laxatives\n3. Willingness to avoid major dietary or lifestyle changes during study.\n\nExclusion Criteria:\n\n1. Use of any antibiotic to treat infection within the 4-weeks prior to study initiation (stable azithromycin dosed 3-times weekly for lung function is to be allowed)\n2. Inability to discontinue standing bowel regimen (including fiber, stool softener, as well as either osmotic or stimulant laxative, pro-kinetic serotonergic agents, or other therapy) 2-weeks prior to study drug initiation (with ability to use osmotic laxative therapy as rescue therapy only).\n3. Severe CFrC as determined by study team\n4. Prior tenapanor usage\n5. Hospitalization within 4-weeks prior to study initiation.\n6. DIOS within 4-weeks prior to study initiation.\n7. Other known\u002Fsuspected mechanical obstruction",{"count":7,"type":22},[305],"Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.",[355,30],"Cystic Fibrosis",[30,355,357],"CFrC","2026-03-17",{"date":360,"type":49},"2026-03-18",{"date":362,"type":49},"2025-06-01",{"date":148,"type":22},{"name":365,"class":56},"Massachusetts General Hospital",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":374,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100629149","preoperative-fish-oil-pn-and-prognosis-after-constipation-surgery-100629149","NCT07470892","Preoperative Fish Oil PN and Prognosis After Constipation Surgery","Impact of Preoperative Fish Oil-Containing Parenteral Nutrition on Prognosis in Patients Undergoing Surgery for Constipation: A Prospective, Multicenter, Real-World Study","FOCP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Meets diagnostic criteria for slow-transit constipation (STC) or megacolon and is scheduled for elective colon surgery.\n3. Nutritional Risk Screening 2002 (NRS2002) score \\>=3.\n4. Receives fish oil-containing parenteral nutrition (PN) for \\>=3 days preoperatively or initiates PN for the first time postoperatively (according to the study cohort definition).\n5. Voluntarily participates in the study and provides signed informed consent.\n\nExclusion Criteria:\n\n1. Mental disorders or other conditions that prevent cooperation with treatment or follow-up.\n2. Pregnant or breastfeeding women, women planning pregnancy \u002F in a pre-pregnancy state, or women with a clear intention to become pregnant during the perioperative period or follow-up.\n3. Contraindications to surgery or parenteral nutrition.\n4. Concurrent enrollment in another study.\n5. No baseline data available before initiation of nutritional support treatment.\n6. Any other condition judged by the investigator to make the participant unsuitable for this study.",{"count":375,"type":22},306,"This is a prospective, multicenter, real-world observational study to evaluate the impact of perioperative parenteral nutrition (PN) with fish oil-containing lipid emulsion on outcomes in adult patients with constipation undergoing elective colon surgery.\n\nThe study will compare two clinical nutrition strategies: (1) PN with fish oil-containing lipid emulsion started before surgery and continued after surgery, and (2) PN with fish oil-containing lipid emulsion started only after surgery. Eligible participants are adults (18-75 years) with slow-transit constipation (STC) or megacolon who are scheduled for elective colon surgery and have nutritional risk (NRS2002 score \\>=3).\n\nThe primary objective is to compare the incidence of postoperative complications between these two PN timing strategies. Secondary objectives include comparison of perioperative nutritional status, postoperative inflammatory status, prognosis, and safety outcomes.\n\nThis study will collect and analyze clinical data, laboratory indicators, perioperative recovery outcomes, follow-up assessments, and safety information in routine clinical practice. Outcomes include postoperative complication rates, changes in nutritional and inflammatory markers, bowel function recovery, length of hospital stay, constipation-related symptoms, quality of life, and adverse events. No experimental intervention will be assigned as part of this observational study.\n\nThe planned sample size is 306 participants. The findings may help optimize perioperative nutritional support strategies for patients with constipation undergoing surgery.",[30,378,379],"Slow Transit Constipation","Megacolon","2026-03-10",{"date":382,"type":49},"2026-03-13",{"date":384,"type":22},"2026-03",{"date":386,"type":22},"2029-09",{"name":388,"class":56},"Qianfoshan Hospital",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":396,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":135,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":57},"100541894","optimization-of-postoperative-bowel-habits-100541894","NCT06335797","Optimization of Postoperative Bowel Habits","Optimization of Postoperative Bowel Habits Following Pelvic Reconstructive Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women ages 18 and older scheduled to undergo vaginal pelvic organ prolapse repair\n\nExclusion Criteria:\n\n* Women younger than 18 years old\n* Those unable to provide consent\n* Preexisting chronic laxative use\n* Conditions that could affect bowel function including, inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, rectovaginal fistula; concurrent bowel surgery; intraoperative bowel injury","FEMALE",{"count":398,"type":22},88,[162],"Project is a trial, in which women undergoing vaginal surgery for pelvic organ prolapse will be randomized 1:1 to a postoperative bowel regimen of either oral senna or rectal bisacodyl suppository.",[30],[71,403,404],"Pelvic Surgery","Laxatives",{"date":406,"type":49},"2026-02-27",{"date":408,"type":49},"2024-10-16",{"date":53,"type":22},{"name":411,"class":56},"Wake Forest University Health Sciences",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":135,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":57},"100485641","phase-2-pyridostigmine-for-the-treatment-of-constipation-in-parkinson-disease-100485641","NCT05603715","Pyridostigmine for the Treatment of Constipation in Parkinson Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Be able to provide signed informed consent\n3. Stated ability and willingness to comply with all study procedures\n4. Able to take oral medications\n5. Females of reproductive potential who are sexually active must be willing to use two of the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (female condom, diaphragm, cervical cap with\u002Fwithout spermicide), hormonal contraception, or intrauterine device; OR one of the previously mentioned methods AND partner must use barrier contraception (male condom with\u002Fwithout spermicide)\n6. Males of reproductive potential who are sexually active must be willing to use the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (male condom with\u002Fwithout spermicide) AND partner must be postmenopausal, use hormonal contraception, have an intrauterine device, or use barrier contraception (female condom, diaphragm, cervical cap with\u002Fwithout spermicide)\n7. Meet United Kingdom Parkinson's Disease Society Brain Bank Criteria:\n\n   A. Diagnosis of a parkinsonism:\n   * Bradykinesia, plus at least one of the following:\n   * Muscular rigidity\n   * 4-6 Hz resting tremor\n   * Postural stability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction\n\n   B. At least three supportive criteria:\n   * Unilateral onset of symptoms\n   * Rest tremor\n   * Progressive symptoms\n   * Persistent asymmetry affecting the side of onset most\n   * Excellent response to levodopa\n   * Severe levodopa-induced chorea\n   * Levodopa response for five years or more\n   * Clinical course of 10 years or more\n8. Fulfill the ROME IV Criteria for Functional Constipation, with a specific requirement that the patient must have three or fewer defecations per week (criterion Ai):\n\n   * Must include two or more of the following:\n\n     i. Three or fewer defecations per week ii. Straining during \\> 25% of defecations iii. Lumpy or hard stools in \\> 25% of defecations iv. Sensation of incomplete evacuation for \\> 25% of defecations v. Sensation of anorectal obstruction\u002Fblockage for \\> 25% of defecations vi. Manual maneuvers to facilitate \\> 25% of defecations\n   * Loose stools are rarely present without the use of laxatives\n   * Insufficient criteria for irritable bowel syndrome\n   * Criteria 1-3 must be fulfilled for at least three months with onset of symptoms at least six months prior to diagnosis\n\nExclusion Criteria:\n\n1. Diagnosis of atypical parkinsonism\n2. Diagnosis of drug-induced parkinsonism\n3. Diagnosis of vascular parkinsonism\n4. Known allergy to pyridostigmine bromide or other study drug components\n5. Current or recent (within 90 days of enrollment) use of pyridostigmine for any reason\n6. History of any bowel surgery\n7. History of bladder or bowel obstruction\n8. Severe asthma or chronic obstructive pulmonary disease\n9. Meet exclusion criteria noted in the UK Parkinson's Disease Society Brain Bank Criteria, at the PI's discretion:\n\n   A.Exclusion of any of the following:\n   * Repeated strokes with stepwise progression of parkinsonian features\n   * Repeated head injury\n   * Definite encephalitis\n   * Oculogyric crises\n   * Neuroleptic treatment at onset of symptoms\n   * Greater than one affected relative\n   * Sustained remission\n   * Strictly unilateral features after 3 years\n   * Supranuclear gaze palsy\n   * Cerebellar signs\n   * Early severe autonomic involvement\n   * Early severe dementia\n   * Babinski sign\n   * Cerebral tumor or communicating hydrocephalus\n   * Negative response to large doses of levodopa\n   * 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure\n10. Significant abnormalities on laboratory analysis (complete blood count, comprehensive metabolic panel, thyroid stimulating hormone) conducted at the screening visit or within the three months prior if available for review\n11. Significant abnormalities on screening electrocardiogram conducted at the screening visit or within the three months prior if available for review\n12. Positive pregnancy test (if female of child-bearing age)\n13. Antibiotic use within two weeks prior to enrollment",{"count":419,"type":22},16,[138],"Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.",[423,30],"Parkinson Disease","2026-02-20",{"date":426,"type":49},"2026-02-23",{"date":428,"type":49},"2022-08-10",{"date":430,"type":22},"2026-12-31",{"name":432,"class":56},"University of Vermont Medical Center",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":135,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":455},"100410350","usefulness-of-high-resolution-manometry-in-constipation-100410350","NCT04623359","Usefulness of High Resolution Manometry in Constipation","MANOCOHR","For patient\n\nInclusion Criteria:\n\n* Age between 18 and 65 years\n* chronic Constipation (\\> 6 months)\n* delayed colonic transit time \\> 100 h\n* normal colonoscopy\n* constipation refractory to at least 1 osmotic and 1 stimulant laxative according French guidelines on constipation ;\n* Affiliated to French national healthcare insurance\n\nExclusion Criteria:\n\n* Patient with constipation being either:\n\n  * With colonic transit time \\\u003C100h\n  * Distal (with radio-opaque markers stasis in the rectum)\n  * From organic origin\n  * Recent (\\\u003C6 mois)\n  * Relieved using osmotic or stimulant laxatives\n* Contra-indication to the use of high resolution manometry insertion\n\n  * Intestinal occlusion\n  * Coagulation disorders, including anti-coagulant treatments\n  * General anesthesia contra-indication\n  * colonoscopy contra-indication\n* failure to perform a colonoscopy in previous attempts\n* medication intake that may impair colorectal motility, including opioids\n* Evolutive inflammatory of neoplasia process\n* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)\n* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia\n* Cardiologic disease that may represent a contraindication to vagal stimulation\n\nFor Healthy volunteers\n\nInclusion Criteria:\n\n* Age between 18 and 65 years\n* Affiliated to French national healthcare insurance\n\nExclusion Criteria:\n\n* Significant digestive evolutive disease\n* constipation with Kess score \\> 11\u002F39 and colonic transit time ≥ 60 h\n* Contra-indication to the use of high resolution manometry insertion\n\n  * Intestinal occlusion\n  * Cardiac disease\n  * Coagulation disorders, including anti-coagulant treatments\n  * General anesthesia contra-indication\n  * colonoscopy contra-indication\n* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)\n* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia",{"count":441,"type":22},76,[162],"Constipation is a frequent symptom that is reported by more than 10% of the general population. In a few case, constipation is resistant to medical standard care, including osmotic and stimulant laxatives. The diagnosis of colonic inertia may be suspected in these patients although diagnostic criteria for colonic inertia may vary from one country to another. In France, the diagnosis of colonic inertia is based on manometric study of the colorectal contractile activity using manometric probe. Using conventional manometric catheters, severe alteration of the colorectal motility is found in a very small subset of patients, who may later benefit from surgery. The recent use of high resolution manometric probe allowed to map more precisely colorectal motility, but whether these new parameters are relevant remains to be assessed. The aim of this study is to assess the diagnostic performance of a new high resolution manometric probe by comparing healthy volunteers to patients suspected of colonic inertia.",[30],[446],"high resolution manometry","2026-02-05",{"date":449,"type":49},"2026-02-06",{"date":451,"type":49},"2023-01-25",{"date":240,"type":22},{"name":454,"class":56},"University Hospital, Rouen",3,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":464,"enrollmentInfo":465,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":467,"conditions":468,"keywords":482,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":57},"100622820","soluble-and-osmotic-fibre-solos-diet-for-constipation-100622820","NCT07388589","Soluble and Osmotic Fibre (SOLOS) Diet for Constipation","The Soluble and Osmotic Fibre (SOLOS) Diet for Functional Bowel Disorders With Constipation","SOLOS","Inclusion Criteria:\n\n* Presented with symptoms of FC, IBS-C, or SIBO-C\n* Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)\n* Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025\n* Did not attend follow-up appointments (Data would be treated as \"intention to treat\" and data points were carried forward for conservative analysis).\n\nExclusion Criteria:\n\n* Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)\n* Started treatment before January 2021\n* Were not due for follow-up before the end of December 2025\n* Symptom and stool data inadequately recorded","70 Years",{"count":466,"type":22},180,"This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.",[30,469,470,471,472,473,474,475,476,477,478,479,480,481],"Constipation - Functional","Constipation Chronic Idiopathic","Constipation Predominant Irritable Bowel Syndrome","Constipation, Signs and Symptoms, Digestive","Constipation-predominant IBS (IBS-C)","Constipation-predominant Irritable Bowel Syndrome","Constipation-predominant Irritable Bowel Syndrome (IBS-C)","Diet Therapy","Diet Modification","Diet, Food and Nutrition","Dietary and Nutritional Therapies","Dietary Fiber","Dietary Fibers",[30,483,484,485,486],"Functional constipation","Constipation-predominant irritable bowel syndrome (IBS-C)","Soluble fiber","osmotic sugar","2026-02-04",{"date":449,"type":49},{"date":490,"type":22},"2026-02-02",{"date":492,"type":22},"2027-03-01",{"name":494,"class":56},"Singapore Institute of Technology",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":135,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":57},"100622795","impact-of-weizmannia-bacillus-coagulans-jbi-yz63-on-gut-health-and-fecal-microbiome-changes-100622795","NCT07388264","Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","Examining the Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","WIZ","Inclusion Criteria Ages of 18 - 50 years Average daily bloating score \\>5 on question 3 of the Modified daily Abdominal, Gas, and Bloating Questionnaire and\u002For bloating for \\>5 days during the past 14 days Body mass index (BMI) 18.5 - 29.9 kg\u002Fm2 (Inclusive) (Individuals \\>29.9 kg\u002Fm2, but \\\u003C25% fat for men and \\\u003C30% fat for women will be accepted into the study. The cohort average of body mass index will not exceed 29.9 kg\u002Fm2) Weight stable for the past three months (defined as less than a 5% variation in body mass over this time) Determined to be healthy through completion of a health history questionnaire Subject agrees to maintain their existing dietary patterns throughout the study period and to report to study investigators any changes particularly as they relate to probiotic-containing or fermented foods Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n\nMinimum baseline physical activity level (defined as at least 30 minutes of moderate intensity exercise at least 4 days per week for the past 3 months) Subject is willing and able to comply with the study protocol. Study participant is not currently enrolled in another clinical trial that involves the administration of some investigative agent Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals Has liver disease or some form of clinically diagnosed hepatic impairment Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL) Diagnosed with or is being treated for some form of thyroid disease Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS) History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n\nParticipant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) Participant has been treated for a gastrointestinal related disorder, complication, or disorder within the past 30 days Positive medical history for any neurological condition or neurological disease Diagnosed with or being treated for any endocrinological disorder or currently used any form of hormone replacement (prescribed\u002Fdoctor ordered or not) Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome Currently prescribed for the first time statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Currently prescribed for the first time hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Current antibiotic use or other prescription or over-the-counter medications that may impact study outcomes Have a known sensitivity or allergy to any of the study products Blood donation in past 60 days Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study Competitive athletes will be excluded History of alcohol or substance abuse in the 12 months prior to screening Current use of anabolic steroids (medically prescribed or otherwise) Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol Report taking a probiotic or other dietary supplement know to impact digestion or gut function in the past 30 days Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%) Currently following a ketogenic or low carbohydrate diet within the past 30 days.\n\nWomen who are pregnant, planning to become pregnant, or lactating currently or within the past six months Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":329,"type":22},[162],"This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo.\n\nApproximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits.\n\nGastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function.\n\nThis study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.",[508,30,509,510],"Gastrointestinal Symptoms","Gut Health","Gastrointestinal Function","2026-01-28",{"date":447,"type":49},{"date":514,"type":49},"2025-06-15",{"date":117,"type":22},{"name":517,"class":56},"Lindenwood University",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":135,"phases":527,"briefSummary":528,"conditions":529,"keywords":532,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":541,"locationsCount":4},"100619431","effect-of-preoperative-abdominal-effleurage-on-postoperative-constipation-100619431","NCT07344532","Effect of Preoperative Abdominal Effleurage on Postoperative Constipation","The Effect of Preoperative Abdominal Superficial Effleurage Training on the Development of Postoperative Constipation in Patients Undergoing Abdominal Surgery","Inclusion Criteria:\n\n* Patients scheduled to undergo abdominal surgery\n* Patients who are able to communicate verbally\n* Patients who agree to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\n* Patients with preoperative constipation\n* Patients with known gastrointestinal diseases affecting bowel motility\n* Patients who are unable to perform abdominal superficial effleurage\n* Patients with cognitive impairment or communication difficulties\n* Patients who refuse to participate in the study",{"count":526,"type":22},42,[162],"This randomized controlled study aims to evaluate the effect of preoperative abdominal superficial effleurage training on the development of postoperative constipation in patients undergoing abdominal surgery. Participants will be randomly assigned to an intervention group receiving abdominal superficial effleurage training in addition to routine care or to a control group receiving routine care only. The effleurage technique will be taught preoperatively and performed by patients postoperatively. Postoperative constipation will be assessed on the 10th postoperative day using the Bristol Stool Form Scale. The findings of this study are expected to contribute to non-pharmacological nursing interventions for the prevention of postoperative constipation.",[30,530,531],"Abdominal Surgery","Postoperative Constipation",[531,530,533,534],"Abdominal Effleurage","Non-Pharmacological Intervention","2026-01-25",{"date":537,"type":49},"2026-01-27",{"date":380,"type":22},{"date":540,"type":22},"2026-09-10",{"name":542,"class":56},"Ege University",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":57},"100618978","the-auxiliary-effect-of-artificial-intelligence-in-the-detection-of-precancerous-lesions-in-proximal-colon-cancer-100618978","NCT07338643","The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer","The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1.Patients with symptoms such as abdominal pain, black stools, constipation, or diarrhea undergo colonoscopy for diagnostic purposes.\n\nExclusion Criteria:\n\n1. Those with inflammatory bowel disease, colorectal cancer and surgical history, as well as those with familial polyposis syndrome\n2. Those with intestinal obstruction or malignant tumors\n3. Patients with colorectal lesions that need to be treated in stages.\n4. Other contraindications for colonoscopy examination.",{"count":551,"type":22},1200,"The investigators conducted a multicenter randomized controlled trial to explore the adjuvant effect of artificial intelligence in the detection of precancerous lesions in the proximal colon.This is a prospective, multicenter, single-blind, parallel randomized controlled trial.During the colonoscopy retraction process, the investigators aimed to compare the detection rates of proximal colon adenomas with and without the assistance of an AI(Artificial Intelligence) diagnostic device.",[554,555,30,31],"Abdominal Pain","Black Stools","2026-01-03",{"date":558,"type":49},"2026-01-14",{"date":560,"type":22},"2026-02-26",{"date":562,"type":22},"2028-08-01",{"name":564,"class":56},"Limian Er",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":65,"sex":18,"minAge":19,"maxAge":572,"enrollmentInfo":573,"targetDuration":4,"studyType":135,"phases":574,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":4},"100616202","oat-milk-for-laxation-100616202","NCT07302542","Oat Milk for Laxation","Impact of Oat Milk Consumption on Gastrointestinal Transit and Defecation Frequency: A Controlled Intervention Trial in Adults","Inclusion Criteria:\n\nClinical diagnosis of non-organic and habitual constipation;\n\nReduced defecation frequency;\n\nIncreased stool hardness;\n\nFewer than 4 bowel movements per week;\n\nExclusion Criteria:\n\nInability to take food orally or inability to comply with the required intake of the test product;\n\nKnown allergy to oats or related products;\n\nUnclear primary gastrointestinal complaints;\n\nPhysical weakness that prevents participation in the trial;\n\nHistory of surgery within the past 30 days that may cause constipation；\n\nRecent constipation caused by severe organic gastrointestinal lesions (e.g., colon cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease);\n\nConstipation accompanied by significant abdominal pain;\n\nAcute gastrointestinal diseases within the past 30 days;\n\nSevere systemic diseases involving the cardiovascular, hepatic, renal, or hematopoietic systems;\n\nOngoing treatment for comorbid conditions that may interfere with study participation;\n\nRecent use of substances related to the tested function that may influence outcome measurements.","60 Years",{"count":21,"type":22},[162],"This study intends to recruit 90-100 constipated participants aged 25-50 years, including an equal number of males and females, from the faculty and logistics staff of Capital Medical University. Participants will be randomly divided into an intervention group (55-60 individuals) and a control group (35-40 individuals). The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 4 weeks, while the control group will not receive oat milk intervention. Both groups will maintain their original lifestyles, including diet, sleep, and exercise, throughout the study period. Baseline surveys, dietary surveys, blood and urine routine tests, blood biochemical indices, and intestinal flora detection will be conducted before and after the intervention. Defecation status will be recorded, and gastrointestinal symptoms will be assessed using a Gastrointestinal Symptom Rating Scale. Statistical analysis will be performed to determine the laxative efficacy of oat milk.",[30],"2025-12-11",{"date":579,"type":49},"2025-12-24",{"date":581,"type":22},"2025-12-15",{"date":583,"type":22},"2026-02-15",{"name":585,"class":56},"Capital Medical University",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":464,"enrollmentInfo":593,"targetDuration":4,"studyType":135,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":57},"100614151","multi-strain-probiotic-effects-on-self-reported-constipation-100614151","NCT07275866","Multi-strain Probiotic Effects on Self-Reported Constipation","A Pilot Study of a Multi-Strain Liquid Probiotic in Individuals Self-reporting Constipation in the General Population.","Inclusion Criteria:\n\n1. Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.\n2. Participant has Cleveland Clinic constipation score (CCCS) of 9-16 at screening call\n3. Participant is willing to discontinue all other therapies for constipation and undergo washout where applicable.\n4. Participant is a male or non-pregnant female and is 18-70 years of age\n5. If WOCBP participant is willing to adhere to one of the following methods of contraception:\n\n   i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).\n\n   or has had a: v) Hysterectomy or has a: vi) Vasectomised partner\n6. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.\n7. Participant has capacity to understand written English.\n8. Participant has a body mass index (BMI) of 18.5 - 39.9kg\u002Fm2 (bounds included).\n9. Participant agrees to follow all pre-test preparation for the ATMO capsule transit study.\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For breastfeeding.\n2. Participants who are planning to significantly change their diet (e.g. weight loss program, becoming vegetarian) during the study period.\n3. Participant has had diarrhoea within 7 weeks of screening period.\n4. Prior abdominal surgery involving resection of the small or large bowel.\n5. Prior bariatric surgery involving resection of the stomach or by-pass procedures.\n6. Type 1 diabetes mellitus.\n7. Known organic or structural GI disease including:\n\n   * Coeliac disease\n   * Inflammatory bowel disease\n   * Diverticulitis\n   * Small bowel strictures\n8. Irritable bowel syndrome where the predominant symptom is pain (assessed via screening questions).\n9. Oropharyngeal dysphagia or difficulty swallowing capsules.\n10. Any other medical condition that the investigator deems may confound results or affect participants' safety in the study.\n11. Any use of prohibited medication that the participant cannot complete appropriate washout for.\n12. Insufficient knowledge of English to complete the daily bowel diary.\n13. Allergy to any component of the supplement, motility bar, lactulose or Zoe blue cookie.\n14. Participant is involved in this study as an investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.\n15. Previous use of the probiotic Symprove.",{"count":594,"type":22},20,[162],"Constipation is a prevalent gastrointestinal condition. Beyond simple lifestyle measures (e.g. increasing fibre intake, hydration, levels of exercise), medical therapies are available for management. However, a sizeable number of sufferers are dissatisfied with drug treatments (either over-the-counter or prescribed), meaning there is an unmet need for alternative therapeutic strategies.\n\nPre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.\n\nThe multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.\n\nThis study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.",[30,598,599],"Probiotic","Probiotic Intervention","2025-12-10",{"date":602,"type":49},"2025-12-18",{"date":604,"type":49},"2025-10-03",{"date":317,"type":22},{"name":607,"class":56},"Dr Anthony Hobson",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":301,"enrollmentInfo":614,"targetDuration":4,"studyType":135,"phases":615,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":57},"100610301","management-of-dyssynergic-defecation-100610301","NCT07225803","Management of Dyssynergic Defecation","Inclusion Criteria:\n\n* Men and women aged 18-80 years who are able and willing to provide written informed consent and to comply with the requirements for the entire study\n* Satisfy Rome III criteria for functional constipation and\u002For irritable bowel syndrome as assessed by questionnaires and objective evidence of dyssynergic defecation on anorectal testing\n\nExclusion Criteria:\n\n* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other diseases that may interfere with the objectives of the study and\u002For pose safety concerns.\n* History of total, hemi- or subtotal colectomy at any time or other abdominal operations within 60 days prior to entry into the study. Segmental resection of the colon (e.g. sigmoid resection) for diverticulitis will be permitted.\n* Current anal fissure\n* Clinically significant structural abnormalities (eg, rectocele \\> 4cm, large enterocele, full thickness rectal prolapse) that, in the opinion of the investigator, are likely contributing to symptoms\n* Current or past history of colon or rectal cancer, scleroderma, inflammatory bowel disease, congenital anorectal abnormalities, solitary rectal ulcer syndrome, rectal resection or pelvic irradiation\n* Pregnant or nursing women, prisoners and institutionalized individuals\n* BMI \\>35 kg\u002Fm2\n* Use of opioid analgesics or GLP-1 receptor agonists. Patients on opioids will be allowed to participate if they have discontinued them for at least 1 week before the date of screening and are willing to stay off them for the duration of the study.\n* Current use of anticholinergics (eg. amitriptyline, hyoscyamine). Patients who use low dose tricyclic antidepressants (nortriptyline or amitriptyline up to 50 mg\u002Fday) will be eligible provided they do not increase the dose during the study period. Patients on higher doses are eligible to participate if it is safe and they are willing to reduce their medication dose at least 3 days (72 hrs) before the date of screening and are willing to stay off them till the study is complete.\n* Current use of laxatives (Ex-lax, senna, herbal supplements), linaclotide, lubiprostone, and prucalopride to treat constipation- patients using these medications will be eligible to participate if they can discontinue the medication at least 3 days (72 hrs.) before the date of screening and are willing to stay off them till the study is complete (As detailed later, all participants can use Miralax throughout the study).\n* Any other factors that increase the risk to participants of participating in the study and\u002For undermine the integrity of the data.",{"count":67,"type":22},[162],"The purpose of this research is to better understand constipation and improve biofeedback treatments.",[618,30],"Dyssynergic Defecation","2025-11-05",{"date":621,"type":49},"2025-11-10",{"date":623,"type":49},"2025-07-18",{"date":625,"type":22},"2029-07",{"name":627,"class":56},"Mayo Clinic",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":635,"maxAge":132,"enrollmentInfo":636,"targetDuration":4,"studyType":135,"phases":638,"briefSummary":639,"conditions":640,"keywords":642,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":655},"100501289","fecobionics-in-biofeedback-therapy-in-dyssynergia-patients-100501289","NCT05807321","Fecobionics in Biofeedback Therapy in Dyssynergia Patients","Fecobionics to Monitor and Predict Biofeedback Therapy in Dyssynergia Patients","Inclusion Criteria:\n\n1. Subject must provide written informed consent.\n2. Age between 21-75 years.\n3. Subjects must fulfill the criteria for obstructed defecation\u002Fdyssynergia and enter the BFT at UCSD or Scripps.\n\nExclusion Criteria:\n\n1. Female who is pregnant or lactating.\n2. Prior abdominal or anorectal surgery or bowel resection.\n3. Diagnosis of fecal incontinence, any anorectal symptoms and drug use that affect anorectal function.\n4. Confirmed or suspected COVID-19 infection.\n5. Severe cardiovascular disease.\n6. Subjects not willing to consent and undergo the specified tests in this study.\n7. Other exclusions, that in the opinion of the investigator, the volunteer is not a suitable subject for the study.","21 Years",{"count":637,"type":22},24,[162],"Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.",[641,30],"Dyssynergia",[643,644,645],"Fecobionics","Biofeedback therapy","Defecation","2025-10-20",{"date":648,"type":49},"2025-10-21",{"date":650,"type":49},"2023-10-03",{"date":652,"type":22},"2027-03-31",{"name":654,"class":56},"The California Medical Innovations Institute, Inc.",2]